Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
| Brand name | METFORMIN HYDROCHLORIDE EXTENDED RELEASE |
| Generic name | METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE |
| Distributed by / for | PD-Rx Pharmaceuticals, Inc. |
| NDC | 72789-009-30 |
| Full product label | metFORMIN HCL ER 500 mg, a) 30 tablets (NDC 72789-009-30); b) 60 tablets (NDC 72789-009-60); c) 90 tablets (NDC 72789-009-90); d) 180 tablets (NDC 72789-009-93); e) 100 tablets (NDC 49483-0623-01) bottles, Rx only PD-Rx Pharmaceuticals Incorporated, Oklahoma City, OK 73127 |
| Recalling firm | PD-Rx Pharmaceuticals, Inc. |
| Distribution | United States. |
| Quantity | 1969 bottles |
| Recall initiated | 2020-06-05 |
| Report date | 2020-07-01 |
| Recall completed | 2021-11-08 |
| Recall number | D-1333-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Oklahoma City OK United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗